OOIR: Observatory of International Research

Papers

(The median citation count of Drug Metabolism Reviews is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
CYP24A1: the pivotal regulator of vitamin D homeostasis, pathophysiology in metabolic and genetic disease, and emerging target for precision medicine	53
Drug transporters in drug disposition – the year 2022 in review	48
Mechanisms of intestinal pharmacokinetic natural product-drug interactions	41
Phase II metabolism in xenobiotic biotransformation: general mechanisms and the underestimated role of microbial systems	36
An in-depth review of PPARγ modulators as anti-diabetes therapeutics	23
Differential modulation of cytochrome P450 enzymes by arsenicals in non-human experimental models	22
Enantioselectivity in some physiological and pathophysiological roles of hydroxyeicosatetraenoic acids	20
New strategy for rational use of antihypertensive drugs in clinical practice in high-altitude hypoxic environments	18
A critical review of analytical tools for the detection of spironolactone and its metabolites	16
Assessing and mitigating pH-mediated DDI risks in drug development – formulation approaches and clinical considerations	15
Cytochrome P450-mediated carbon-carbon bond formation in drug metabolism	15
Multimolecular interactions from Chinese medicines activate nuclear receptor conformational changes: a potential strategy for anti-inflammatory therapy	14
Biopolymers as promising vehicles for drug delivery to the brain	13
Redox enzyme networks shaping cancer drug metabolism and therapeutic resistance	13
Genetic determinants of paclitaxel-induced peripheral neuropathy: a review of current literature	12
Transporter-mediated drug-drug interactions: regulatory guidelines, in vitro and in vivo methodologies and translation, special population	12
Drug transporters in drug disposition – highlights from the year 2024	12
Clinical pharmacokinetics of nebivolol: a systematic review	11
Metabolism of new drug modalities research advances – 2024 year in review	11
Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice	10
A transcriptional regulatory network of HNF4α and HNF1α involved in human diseases and drug metabolism	10
Scaling factors to inform in vitro - in vivo extrapolation from preclinical and livestock animals: state o	10
Biotransformation research advances—2025 year in review	9
Pharmacomicrobiomics in precision pharmacotherapy: bidirectional microbial-drug interactions as a key determinant of therapeutic response	9
Effects of intestinal flora on pharmacokinetics and pharmacodynamics of drugs	8

Favipiravir, remdesivir, and lopinavir: metabolites, degradation products and their analytical methods	8
Molecular insights into doxorubicin-induced cardiotoxicity and phytochemical-based cardioprotection: challenges and future strategies	8
Aldehyde oxidase mediated drug metabolism: an underpredicted obstacle in drug discovery and development	7
Correction	7
Advances in drug resistance of osteosarcoma caused by pregnane X receptor	7
In silico ADME and target prediction studies of Alogliptin as drug molecule	7
In-depth understanding of the structure-based reactive metabolite formation of organic functional groups	7
Metabolism of m -CPP, trazodone, nefazodone, and etoperidone: clinical and forensic aspects	6
Biotransformation research advances – 2023 year in review	6
Simplified approaches to kinetic isotope effects in cytochrome P450-catalyzed reactions and relevance to deuterated drugs	6
Correction	6
Analytical techniques for methyldopa and metabolites: a comprehensive review	6
Cytochrome P450-derived arachidonic acid metabolites as emerging therapeutic targets in menopause-associated cardiac hypertrophy	5
3D self-assembled nanocarriers for drug delivery	5
Physiological and pathophysiological roles of hepoxilins and their analogs	5
Interaction of drugs with gut microbiota modulators	4
How gut microbiota modulate anesthetic drug response and perioperative outcomes	4
The potential impact of CYP and UGT drug-metabolizing enzymes on brain target site drug exposure	4
Relationship between blood–brain barrier changes and drug metabolism under high-altitude hypoxia: obstacle or opportunity for drug transport?	4
Melatonin in cancer biology: pathways, derivatives, and the promise of targeted delivery	4
The role and current research status of resveratrol in the treatment of osteoarthritis and its mechanisms: a narrative review	4
Cutting-edge strategies and critical advancements in characterization and quantification of metabolites concerning translational metabolomics	4
Relevance of reactive metabolites and covalent binding to drug candidate selection	4
Pregnane X receptor (PXR/NR1I2): linking drug metabolism, bile acid detoxification, and cholesterol homeostasis	4
Antitubercular drugs induced liver injury: an updated insight into molecular mechanisms	4
Enzyme-mediated drug-drug interactions: a review of in vivo and in vitro methodologies, regulatory guidance, and translation to the clinic	4